Kalorama Identifies Four Trends to Watch in Autoimmune Immunoassay Market
Tuesday, November 16, 2021
Healthcare publisher, Kalorama Information, shares insights from its recent report on the Autoimmune Immunoassay Market.
ARLINGTON, Va., Nov. 8, 2021 /PRNewswire-PRWeb/ -- The market for autoimmune immunoassays will total an estimated $971.7 million in 2021 and is forecast to exceed $1 billion by 2026, according to Autoimmune Immunoassay Brief, a recent report by leading medical market researcher Kalorama Information.
The autoimmune immunoassays market--including lab-based autoimmune immunoassays and POC-based autoimmune immunoassays--is only a small part of the total IVD immunoassay diagnostic testing market, yet the prevalence of autoimmune diseases are rising and there continues to be improved sensitivity for testing. In the report, Kalorama Information's estimates includes revenues for reagents and instruments for the testing of autoimmune immunoassays. It does not include services.
Competition within this market is expected to increase dramatically. However, in fledgling autoimmune IVD diagnostic testing markets, a golden opportunity exists to capitalize on new testing innovations without significant competition. Among companies already successfully operating in the segment, Thermo Fisher and INOVA standout due to their robust autoimmune immunoassay offerings and impressive pipelines.
"Currently, a considerable number of diagnostic tests are available or in development for the detection of autoimmune diseases. Because of this potentially large and growing market, vast opportunity exists for discovery and advancement in this arena," says Bruce Carlson, publisher for Kalorama Information.
Regarding present and future growth opportunities, Kalorama Information has identified several important trends. These include, but aren't limited to:
-- Trend 1: There are vast opportunities for manufacturers of autoimmune
diagnostic testing products in the autoimmune arena
Because most autoimmune diseases are of unknown etiology, the potential discovery of many other autoimmune diseases will likely lead to increased opportunities in the discovery, manufacture and marketing of autoimmune IVD diagnostic testing products.
-- Trend 2: Women are disproportionately affected by autoimmune disease
Because the population is aging and there will be more women aging, they are going to be affected more often than men with autoimmune diseases. This will likely create a large demographic that will benefit from novel and sophisticated autoimmune IVD diagnostic testing.
-- Trend 3: Sophistication in testing is leading to more automated
effective testing
Diagnostic companies are continuing to gradually improve their fully automated platforms. In addition, many companies are working to develop innovative new platforms. Demand for healthcare and diagnostic tests in all the major markets is driven by aging populations and increased incidence of autoimmune conditions. Considering the demand for these tests, they have been reformulated for automated analyzers where the cost per test is traditionally lower.
-- Trend 4: Testing needs to be cost effective but precise to identify
autoimmune diseases
The commercialization of sophisticated new IVD products and technologies comes as a double-edged sword--some of these new devices and technologies are expected to carry a high price tag and the payment infrastructure in most countries has not evolved to cover many of the newer approaches to patient management. The result, as is often the case, is that technology is far ahead of healthcare regulations and reimbursement plans. The onus is, therefore, on manufacturers to prove their new intervention is not only effective but also supplies a cost-effective treatment alternative.
For more information purchase Allergy Immunoassay Brief, available at https://kaloramainformation.com/product/autoimmune-immunoassay-brief/
About Kalorama Information:
Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.
Media Contact
Bruce Carlson, Kalorama Information, 703-783-1747, bruce.carlson@kaloramainformation.com
SOURCE Kalorama Information
|
|
|
|
|
 |
The New Identity Theft Crisis: AI Scams, Child Victims, and Credit Damage Are All Spiking | Jan 22, 2026
|
|
AllSci Launches Hypothesis Publishing: A Seamless Way to Share, Connect, and Advance Scientific Ideas | Jan 22, 2026
|
|
Canadian Fintech Tuhk Inc., Founded by Ethoca and NuData Security Veterans, Raises US$6 Million Seed Round Led by FINTOP, with Lloyds Banking Group and Capital One Ventures | Jan 22, 2026
|
|
Darwin CX Caps a Banner Year with AI Launch, Sold-Out Events, and Industry Book Launch | Jan 22, 2026
|
|
Fintech Startup BON Credit Secures $3.5 Million In Funding | Jan 22, 2026
|
|
PayDo Launches Unified Payment Infrastructure Suite for Digital Businesses | Jan 22, 2026
|
|
Nudge Security Unveils Industry's Most Comprehensive AI Security Governance Platform | Jan 22, 2026
|
|
IoTeX Publishes MiCA-Compliant Whitepaper for IOTX, Enabling EU-Wide Alignment Under the New Regulatory Framework | Jan 22, 2026
|
|
Gametime Launches "12 Days of Gametime" Holiday Giveaway in Partnership with Barstool Sports | Jan 22, 2026
|
|
TSX Venture Exchange Market Data Now Available Across Over 40 Blockchains via Chainlink | Jan 22, 2026
|
|
|
